On January 6, 2022 Sapience Therapeutics, Inc., a biotechnology company focused on the discovery and development of peptide therapeutics to address difficult-to-treat cancers, reported the initiation of Phase 2 and dosing of the first patient in the glioblastoma (GBM) expansion cohort in the ongoing Phase 1-2 Study of ST101 (Press release, KemPharm, JAN 6, 2022, View Source [SID1234598359]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The expansion cohorts in the study include patients with refractory, locally advanced and metastatic cutaneous melanoma, hormone-receptor-positive breast cancer, castrate-resistant prostate cancer, and GBM, and are designed to determine proof-of-concept efficacy of ST101 and provide further insights into safety, pharmacokinetics (PK) and pharmacodynamics (PD).
"Following successful conclusion of dose escalation, we are pleased to expand our ST101 program with the initiation of Phase 2 and dosing of the first patient in the GBM cohort at Columbia University Irving Medical Center," commented Dr. Alice Bexon, Sapience’s Chief Medical Officer. "ST101 has shown very encouraging efficacy and safety in Phase 1, with demonstrated clinical proof-of-concept with a durable clinical response and evidence of long-lasting stable disease in several patients with refractory solid tumors. We are excited about the potential of ST101 to treat these four aggressive cancers."
Dr. Barry Kappel, Sapience’s founder, CEO and President, added, "Moving to Phase 2 and testing ST101 in our tumor specific expansion cohorts is a great moment for us at Sapience. Having the first patient be treated at Columba University, where Sapience licensed its initial intellectual property from, makes this significant milestone even more meaningful for us."
About ST101 and the Phase 1-2 Study
ST101, a peptide antagonist of C/EBPβ, is currently being evaluated in the Phase 2 portion of an ongoing Phase 1-2 clinical study in patients with advanced unresectable and metastatic solid tumors (NCT04478279). This is an open-label, two-part, Phase 1-2 dose-finding study designed to determine the safety, tolerability, PK, PD, and proof-of-concept efficacy of ST101 in patients with advanced solid tumors. The study consists of two phases: a Phase 1 dose escalation/regimen exploration phase and a Phase 2 expansion phase. In the ongoing study, ST101 has demonstrated clinical proof-of-concept with a RECIST 1.1-confirmed partial response (PR) in a patient with cutaneous melanoma and evidence of long-lasting stable disease in several additional patients. Sapience has initiated Phase 2 and has dosed the first patient in the GBM expansion cohort. Sapience also plans to initiate dosing in the additional expansion cohorts in refractory, locally advanced or metastatic hormone-receptor-positive breast cancer, metastatic cutaneous melanoma and castrate-resistant prostate cancer. ST101 has been granted Fast Track designation for recurrent GBM and advanced cutaneous melanoma in patients who have disease progression on or after anti-PD-1/anti-PD-L1 therapy, as well as Orphan designation from the U.S. Food and Drug Administration and the European Commission for the treatment of glioma.